85 related articles for article (PubMed ID: 23176524)
1. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
Jayanthan A; Cooper TM; Hoeksema KA; Lotfi S; Woldum E; Lewis VA; Narendran A
Leuk Lymphoma; 2013 Jul; 54(7):1505-16. PubMed ID: 23176524
[TBL] [Abstract][Full Text] [Related]
2. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
3. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
4. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.
Podesta JE; Sugar R; Squires M; Linardopoulos S; Pearson AD; Moore AS
Leuk Res; 2011 Sep; 35(9):1273-5. PubMed ID: 21665275
[TBL] [Abstract][Full Text] [Related]
5. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S
Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229
[TBL] [Abstract][Full Text] [Related]
6. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
[TBL] [Abstract][Full Text] [Related]
7. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
[TBL] [Abstract][Full Text] [Related]
8. Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.
Shah M; Gallipoli P; Lyons J; Holyoake T; Jørgensen H
Blood Cells Mol Dis; 2012 Mar; 48(3):199-201. PubMed ID: 22325915
[No Abstract] [Full Text] [Related]
9. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.
Vormoor B; Veal GJ; Griffin MJ; Boddy AV; Irving J; Minto L; Case M; Banerji U; Swales KE; Tall JR; Moore AS; Toguchi M; Acton G; Dyer K; Schwab C; Harrison CJ; Grainger JD; Lancaster D; Kearns P; Hargrave D; Vormoor J
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27905678
[TBL] [Abstract][Full Text] [Related]
10. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Howard S; Berdini V; Boulstridge JA; Carr MG; Cross DM; Curry J; Devine LA; Early TR; Fazal L; Gill AL; Heathcote M; Maman S; Matthews JE; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Rees DC; Reule M; Tisi D; Williams G; Vinković M; Wyatt PG
J Med Chem; 2009 Jan; 52(2):379-88. PubMed ID: 19143567
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents.
Jayanthan A; Ruan Y; Truong TH; Narendran A
PLoS One; 2014; 9(7):e102741. PubMed ID: 25048812
[TBL] [Abstract][Full Text] [Related]
12. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
Hawkins LM; Jayanthan AA; Narendran A
Pediatr Res; 2005 Mar; 57(3):430-7. PubMed ID: 15659698
[TBL] [Abstract][Full Text] [Related]
13. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.
Jayanthan A; Hofmann B; Meier-Stephenson V; Perinpanayagam M; Dunn SE; Boklan J; Trippett TM; Truong TH; Narendran A
J Pediatr Hematol Oncol; 2019 Aug; 41(6):e359-e370. PubMed ID: 30702467
[TBL] [Abstract][Full Text] [Related]
14. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Foran J; Ravandi F; Wierda W; Garcia-Manero G; Verstovsek S; Kadia T; Burger J; Yule M; Langford G; Lyons J; Ayrton J; Lock V; Borthakur G; Cortes J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):223-30. PubMed ID: 24355079
[TBL] [Abstract][Full Text] [Related]
16. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
Chen YP; Lin HJ; Chen JS; Tsai MY; Hsieh HP; Chang JY; Chen NF; Chang KC; Huang WT; Su WC; Yang ST; Chang WC; Hung LY; Chen TY
Int J Cancer; 2014 Aug; 135(3):751-62. PubMed ID: 24382688
[TBL] [Abstract][Full Text] [Related]
17. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
19. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
20. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Walsby E; Walsh V; Pepper C; Burnett A; Mills K
Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]